We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+16.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$276M
AUM Growth
+$59.5M
Cap. Flow
+$34.9M
Cap. Flow %
12.66%
Top 10 Hldgs %
29.49%
Holding
157
New
25
Increased
65
Reduced
12
Closed
31

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$7.96M
2
HES
Hess
HES
+$4.24M
3
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.06M
4
SP
SP Plus Corporation
SP
+$3.96M
5
PATH icon
UiPath
PATH
+$2.41M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$5.76M
2
VMW
VMware, Inc
VMW
+$5.59M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.04M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.03M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 45.71%
2 Technology 11.75%
3 Consumer Discretionary 6.51%
4 Industrials 5.31%
5 Consumer Staples 4.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALV icon
101
Autoliv
ALV
$8.96B
$798K 0.29%
7,244
+2,000
+38% +$199K
NU icon
102
Nu Holdings
NU
$65.9B
$779K 0.28%
+93,461
New +$755K
BABA icon
103
Alibaba
BABA
$306B
$764K 0.28%
9,857
+2,900
+42% +$231K
ALPN
104
DELISTED
Alpine Immune Sciences Inc
ALPN
$760K 0.28%
39,861
– –
ITCI
105
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$684K 0.25%
9,545
– –
RYTM icon
106
Rhythm Pharmaceuticals
RYTM
$7.77B
$660K 0.24%
+14,362
New +$453K
PTGX icon
107
Protagonist Therapeutics
PTGX
$9.6B
$650K 0.24%
+28,359
New +$496K
RVMD icon
108
Revolution Medicines
RVMD
$44.1B
$650K 0.24%
22,650
+4,645
+26% +$112K
VRNA
109
DELISTED
Verona Pharma
VRNA
$645K 0.23%
32,449
+2,576
+9% +$38K
TAL icon
110
TAL Education Group
TAL
$6.75B
$619K 0.22%
49,000
-1,300
-3% -$13.5K
ROIV icon
111
Roivant Sciences
ROIV
$25.5B
$617K 0.22%
+54,930
New +$535K
PLRX icon
112
Pliant Therapeutics
PLRX
$63.8M
$616K 0.22%
34,039
+3,316
+11% +$50.4K
PCVX icon
113
Vaxcyte
PCVX
$8.81B
$585K 0.21%
9,321
-1,927
-17% -$100K
CRNX icon
114
Crinetics Pharmaceuticals
CRNX
$8.95B
$566K 0.21%
+15,899
New +$488K
LKFT
115
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.88B
$527K 0.19%
12,953
-694
-5% -$25.5K
EDU icon
116
New Oriental
EDU
$8.84B
$520K 0.19%
7,100
+700
+11% +$48.6K
GERN icon
117
Geron
GERN
$1.05B
$507K 0.18%
240,234
+39,341
+20% +$76.5K
UTHR icon
118
United Therapeutics
UTHR
$22.1B
$506K 0.18%
2,299
– –
BASE
119
DELISTED
Couchbase
BASE
$413K 0.15%
+18,326
New +$336K
ARGX icon
120
argenx
ARGX
$54.1B
$406K 0.15%
1,067
– –
AMLX icon
121
Amylyx Pharmaceuticals
AMLX
$2.63B
$388K 0.14%
26,349
– –
ASND icon
122
Ascendis Pharma A/S
ASND
$16.7B
$356K 0.13%
2,828
-3,070
-52% -$306K
LI icon
123
Li Auto
LI
$12.4B
$336K 0.12%
8,966
– –
MDGL icon
124
Madrigal Pharmaceuticals
MDGL
$12.4B
$331K 0.12%
1,431
-1,614
-53% -$282K
UDMY
125
DELISTED
Udemy
UDMY
$272K 0.1%
+18,497
New +$230K
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q4 2023 Portfolio in Review

As of Q4 2023, HighVista Strategies held 157 positions worth $276M, up 28% from $216M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $34.9M of net new capital in Q4 2023, opening 25 new positions and adding to 65 existing holdings. Its largest new stake was Spyre Therapeutics: 577,616 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Micron Technology, an estimated $780K trimmed.

  • HighVista Strategies's largest Q4 2023 buy was Spyre Therapeutics: 577,616 shares worth $12.4M.
  • HighVista Strategies added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023, an estimated $2.08M increase.
  • HighVista Strategies's biggest Q4 2023 reduction was Micron Technology, cutting an estimated $780K.
  • HighVista Strategies fully exited Activision Blizzard in Q4 2023, selling an estimated $5.76M.
  • HighVista Strategies's ten largest holdings make up 29% of its $276M portfolio in Q4 2023.
  • HighVista Strategies opened 25 new positions and closed 31 in Q4 2023.
  • HighVista Strategies's portfolio value rose 28% quarter-over-quarter to $276M.

Based on HighVista Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.